Can I read Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients on EtoBox?

Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients by Jiaqi Bo; Baohua Yu; Rui Bi; Xiaoli Xu; Yufan Cheng; Xiaoyu Tu; Qianming Bai; Wentao Yang; Ruohong Shui is a Medicine article available to read on EtoBox.

What is Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients about?

ER and HER2 status may change after neoadjuvant therapy (NAT) in breast cancers. There have been variable discordance rates of ER and HER2 status pre-and post-NAT in previous studies. Few studies have focused on conversion of ER-low and HER-low expression status after NAT. We aimed to assess the evolution in ER and HER2 status after NAT in breast cancers. Background: Few studies have focused on converting ER-low-positive and HER2-low status following neoadjuvant therapy (NAT). We aimed to assess the evolution in ER and HER2 status after NAT in breast cancer patients. Patients and Methods: Our study included 481 patients with residual invasive breast cancer after NAT. ER and HER2 status were assessed in the primary tumor and residual disease, and associations between ER and HER2 conversion and clinicopathological factors were explored. Results: In primary tumors, 305 (63.4%) cases were ER-positive (including 36 cases of ER-low-positive), 176 (36.6%) were ER-negative. In residual disease, ER status changed in 76 (15.8%) cases, of which 69 cases switched from positive to negative. ER-low-positive tumors (31/36) were the most likely to change. In primary tumors, 140 (29.1%) tumors were

Who reads Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients?

Author

Jiaqi Bo; Baohua Yu; Rui Bi; Xiaoli Xu; Yufan Cheng; Xiaoyu Tu; Qianming Bai; Wentao Yang; Ruohong Shui

Publisher

Elsevier BV

Published

2023

Language

EN

Field

Medicine (Health Sciences)